Svenska

The exercise period for warrants series TO 2 in Qlife Holding begins today

Report this content

The exercise period for warrants series TO 2 that were issued in conjunction with Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of units in October 2022 (the “Rights Issue”) begins today, 7 June 2023.

Terms for warrants series TO 2 in brief:

  • The exercise price has been set to SEK 0.21 per share. The exercise price has been defined as seventy (70) per cent of the volume-weighted average price of the Company’s share during the period 22 May – 2 June 2023.
  • The exercise period runs from 7 – 21 June 2023.
  • Each warrant entitles the holder to subscribe for 1.08 shares. Upon exercise of all 7,587,609 outstanding warrants, a maximum of 8,194,617 shares may be issued.
  • If the warrants are fully exercised, the Company will receive approximately MSEK 1.7 before issue costs.
  • Upon full exercise of all warrants, the number of shares in Qlife will increase with 8,194,617 to 653,616,093 shares, and the share capital will increase with SEK 655,569.36 to SEK 52,289,287.44.
  • The outcome is planned to be announced on 23 June 2023.

In total, Qlife issued 2,884,980 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 2. The exercise period of the warrants will run from 7 – 21 June 2023. One (1) warrant entitles the right to subscribe for 1.08 new shares in the Company at an exercise price of SEK 0.21, which is corresponding to seventy (70) per cent of the volume-weighted average price of the Company’s share during the period from and including 22 May 2023 up to and including 2 June 2023. In connection with the Company’s rights issue in April 2023, recalculation was made of the highest subscription price as well as of the number of shares that each warrant series TO 2 entitles the right to subscribe for, where the previous highest subscription price amounted to SEK 10 and each warrant entitled to subscription of one (1) share.

In the event of full exercise of all warrants, the Company will receive approximately MSEK 1.7 before issue costs. In order for the warrants not to expire and lose their value, they must be actively sold by 19 June 2023 at the latest, or be exercised no later than 21 June 2023.  

Note that warrants that have not been actively sold by 19 June 2023 at the latest, or been exercised no later than 21 June 2023, will expire and lose their value.

Exercise of warrants series TO 2

Trustee-registered warrants

If the warrant holder holds warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercise of the warrants.

Directly registered warrants (securities account)

Directly registered warrant holders can order an application form via info@eminova.se or by phone on +46 8-684 211 00. Payment is made in accordance with the instructions in the application form. Both the application form and payment must be submitted to Eminova Fondkommission AB by 15.00 CEST on 21 June 2023 at the latest.

The information was submitted for publication, through the agency of the contact person set out below, on 2023-06-07 08:30 CET.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today's view on healthcare into tomorrow's focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health - so that they can move beyond reactive care towards proactive wellbeing. It's how we contribute to improving quality of life for every individual and for the greater society.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor.
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Qlife. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Qlife has only taken place through the prospectus that Qlife published on 30 September 2022.

Prenumerera